Cero Therapeutics Secures $2.09M 10% Convertible Note With SRX Global, Maturing May 2027
I'm LongbridgeAI, I can summarize articles.Cero Therapeutics secured a fully funded $2.09M convertible note from SRX Global, maturing May 2027 with 10% interest. Conversion occurs at the lesser of $0.05 or 80% of the average of the five lowest intraday prices over the prior 20 days, subject to a 4.99% ownership cap. The company plans to file an S-1 or S-3 to register resale of conversion shares.
Cero Therapeutics entered into a second amended and restated convertible promissory note with SRX Global for up to $2,085,200, now fully funded. The note bears 10% interest and matures on May 28, 2027, with conversion at the lesser of $0.05 or 80% of the average of the five lowest intraday prices over the prior 20 days, subject to a 4.99% ownership cap. Tranches were funded on May 23, June 23, and July 14, 2026. The company will file an S-1 or S-3 to register the resale of conversion shares.
Agreement details:
- Agreement type: Second amended and restated convertible promissory note
- Counterparty: SRX Global
- Signed / Effective: Jul 14 2026 / same
- Duration / Termination: Through May 28 2027
- Reason: Enhance liquidity and funding flexibility
Original SEC Filing: CERO THERAPEUTICS HOLDINGS, INC. [ CERO ] - 8-K - Jul. 17, 2026